With a bunch of biologic drugs in development, Roche's Genentech sees the need for more production capacity. To meet it, the biotech is expanding a fill/finish facility in Oregon, investing more than $100 million on the project and adding dozens of jobs there.
Roche's Genentech subsidiary is embarking on a $125 million project that will take Roche's investment in biologics production to over $1 billion and add 100 more jobs to the 500 Roche initially said its biologics expansion would create.
California's Alameda County has held fast against Big Pharma pushback to its drug take-back ordinance that requires drugmakers to fund a program for accepting and destroying unused meds. Now San Francisco has passed its own ordinance to require the same thing.
Genentech begs to differ with a survey finding that its new distribution method is delaying treatment for some cancer patients. Hospitals may be complaining in press releases about the change to Herceptin, Rituxan and Avastin purchasing, but they're not reporting particular treatment problems to the company, Genentech says.
Seventy percent of the 20 best-selling drugs in Taiwan are for treating blood pressure, strokes and other chronic diseases.
Hospitals continue to pressure Roche's Genentech to stop using specialty distributors for some of its cancer meds. The latest move is a survey in which not only do respondents claim the change is costing them money, but more than a quarter said it is delaying patient care, The Wall Street Journal blog Pharmalot reports.
Top hospitals are still irate about Genentech's decision to move its best-selling cancer drugs to specialty distributors. And they're not giving up on persuading the company to change back.
Respiratory devicemaker PARI picked up an approval from the FDA for its eRapid nebulizer system, which is the first electronic one to deliver Genentech's cystic fibrosis treatment Pulmozyme.
Back in January of 2012, Third Rock's upstart epigenetics play Constellation Pharmaceuticals landed a three-year deal with a marquee development partner. Genentech agreed to step in, provided a cash commitment of $95 million to cover part of the Cambridge, MA-based biotech's R&D overhead, and added an option to buy the company. Now the collaboration part of the deal is complete, and on Friday the biotech quietly laid off 23 staffers as it sketched out a path that would allow it to go it alone--if Genentech doesn't acquire the company by its deadline later this year.
Having given a $60 million boost to 23andMe last week, Genentech has now turned to J. Craig Venter's Human Longevity for help sequencing and analyzing tens of thousands of genomes.